Last reviewed · How we verify
NCT01691261
A Study of Implantation of Retinal Pigment Epithelium in Subjects with Acute Wet Age Related Macular Degeneration
Phase 1 trial testing PF-05206388 in Age Related Macular Degeneration in 9 participants. Completed in 24 June 2024.
10 October 2023
Quick facts
| Lead sponsor | Moorfields Eye Hospital NHS Foundation Trust |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 14 October 2021 |
| Primary completion | 10 October 2023 |
| Estimated completion | 24 June 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- PF-05206388 — full drug profile →
Conditions studied
- Age Related Macular Degeneration — all drugs for Age Related Macular Degeneration →
Sponsor
Moorfields Eye Hospital NHS Foundation Trust
Who can join
60 and older, any sex, with Age Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase 1 trial of retinal pigment epithelium replacement in subjects with wet age-related macular degeneration in whom there is rapidly progressing vision loss
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01691261
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age Related Macular Degeneration
Currently open trials in the same condition.
- NCT07461441 — Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal · Phase 3 · recruiting
- NCT07235527 — Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degener · recruiting
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT03102138 — Retinal Pigment Epithelium Safety Study for Patients in B4711001 · active not recruiting
- NCT05698316 — A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Predicti · active not recruiting
Other Moorfields Eye Hospital NHS Foundation Trust trials
Trials by the same sponsor.
- NCT06974162 — Metagenomics for Ocular Inflammation · recruiting
- NCT06689397 — Investigating Epstein-Barr Virus Associated Conjunctivitis · enrolling by invitation
- NCT06528509 — AI-Enhanced Consent for Cataract Surgery · NA · not yet recruiting
- NCT03102138 — Retinal Pigment Epithelium Safety Study for Patients in B4711001 · active not recruiting
- NCT05543889 — Evaluation of Clinical Decisions and Assessment of Those at Risk of Primary Angle Closure by Community Optometrists · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01691261 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Moorfields Eye Hospital NHS Foundation Trust
- Last refreshed: 22 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01691261.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing